-
Founded in:
2005-10-18 -
Country:
China -
Address:
No. 273-A, Nanhai Avenue, National High-tech Zone, Haikou City -
Tax NO.:
91460000780701210W -
Registered Funds:
40 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Tegafur |
This product is a derivative of fluorouracil. It is activated by the liver in the body and converted into fluorouracil to exert its anti-tumor activity, interfere with DNA and RNA synthesis, and mainly acts on the S phase. It is a cell cycle-specific drug. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil.
More
This product is a derivative of fluorouracil. It is activated by the liver in the body and converted into fluorouracil to exert its anti-tumor activity, interfere with DNA and RNA synthesis, and mainly acts on the S phase. It is a cell cycle-specific drug. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. |
17902-23-7 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Esmolol hydrochloride |
Selective (cardioselective) β1 adrenergic receptor blocker, with rapid onset, short duration of action, and no obvious intrinsic sympathomimetic activity or membrane stabilizing effect at therapeutic doses. The elimination half-life after intravenous injection is about 9 minutes. It mainly inhibits β1 adrenergic receptors located in the myocardium, and in large doses also has a blocking effect on β2 adrenergic receptors in tracheal and vascular smooth muscle.
More
Selective (cardioselective) β1 adrenergic receptor blocker, with rapid onset, short duration of action, and no obvious intrinsic sympathomimetic activity or membrane stabilizing effect at therapeutic doses. The elimination half-life after intravenous injection is about 9 minutes. It mainly inhibits β1 adrenergic receptors located in the myocardium, and in large doses also has a blocking effect on β2 adrenergic receptors in tracheal and vascular smooth muscle. |
81161-17-3 | 21 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ondansetron hydrochloride |
This product is a potent, highly selective 5-HT3 receptor antagonist with a strong antiemetic effect. It exerts an antiemetic effect by antagonizing the 5-HT receptors of neurons located in the peripheral and central nervous systems, and is used to prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery.
More
This product is a potent, highly selective 5-HT3 receptor antagonist with a strong antiemetic effect. It exerts an antiemetic effect by antagonizing the 5-HT receptors of neurons located in the peripheral and central nervous systems, and is used to prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery. |
103639-04-9 | 26 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ondansetron hydrochloride |
This product is a potent, highly selective 5-HT3 receptor antagonist with a strong antiemetic effect. It exerts an antiemetic effect by antagonizing the 5-HT receptors of neurons located in the peripheral and central nervous systems. It is used to treat nausea and vomiting after chemotherapy, radiotherapy, and surgery. In addition, it can also inhibit nausea induced by opioids, but the specific mechanism is still unclear.
More
This product is a potent, highly selective 5-HT3 receptor antagonist with a strong antiemetic effect. It exerts an antiemetic effect by antagonizing the 5-HT receptors of neurons located in the peripheral and central nervous systems. It is used to treat nausea and vomiting after chemotherapy, radiotherapy, and surgery. In addition, it can also inhibit nausea induced by opioids, but the specific mechanism is still unclear. |
103639-04-9 | 26 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Tegafur |
This product is a derivative of fluorouracil. It is activated by the liver in the body and gradually converted into fluorouracil to play an anti-tumor role. It can interfere with and block the synthesis of DNA, RNA and protein, and mainly acts on the S phase. It is a cell cycle-specific drug of anti-pyrimidine. Its mechanism of action, efficacy and anti-tumor spectrum are similar to those of fluorouracil, but it has a long-lasting effect, good absorption and low toxicity. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. No serious bone marrow suppression was observed in the chronic toxicity experiment, and the effect on immunity was relatively mild.
More
This product is a derivative of fluorouracil. It is activated by the liver in the body and gradually converted into fluorouracil to play an anti-tumor role. It can interfere with and block the synthesis of DNA, RNA and protein, and mainly acts on the S phase. It is a cell cycle-specific drug of anti-pyrimidine. Its mechanism of action, efficacy and anti-tumor spectrum are similar to those of fluorouracil, but it has a long-lasting effect, good absorption and low toxicity. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. No serious bone marrow suppression was observed in the chronic toxicity experiment, and the effect on immunity was relatively mild. |
17902-23-7 | 10 |